<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601013</url>
  </required_header>
  <id_info>
    <org_study_id>DAPT-TR</org_study_id>
    <nct_id>NCT03601013</nct_id>
  </id_info>
  <brief_title>Demographical and Clinical Profile of Patients on Dual Ant覺platelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey</brief_title>
  <official_title>Demographical and Clinical Profile of Patients on Dual Ant覺platelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Academy Society, Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Academy Society, Turkey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary Artery Disease (CAD) is leading cause of death worldwide. Most of them underwent&#xD;
      coronary angiography and they have to use dual anti-platelet therapy. As mentioned novel&#xD;
      guidelines for CAD, the estimated number of patients requiring dual anti-platelet therapy has&#xD;
      increased over time, and DAPT time is controversial. Acting on the behalf of 2017 ESC focused&#xD;
      update on dual anti-platelet therapy in coronary artery disease developed in collaboration&#xD;
      with EACTS guideline, this study is amid to determine PRECISE-DAPT score which predicts out&#xD;
      of hospital bleeding risk in patients receiving dual anti-platelet treatment and to detect&#xD;
      the prevalence of patients with high bleeding risk, and to determine DAPT score which&#xD;
      predicts benefit/risk ratio of continuing or discontinuing dual ant-iplatelet therapy after&#xD;
      12 months and to detect the prevalence of patients with high ischemic or hemorrhagic&#xD;
      complication risk in centers included in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design&#xD;
&#xD;
      The study is a national, multicenter, non-interventional, observational, prospective&#xD;
      registry.&#xD;
&#xD;
      Population&#xD;
&#xD;
      Patients older than 18 years old of age, have acute coronary syndrome or percutaneous&#xD;
      coronary intervention electively and with available admission hemoglobin, white blood cell&#xD;
      and creatine clearance data will be enrolled for Precise-DAPT,and Patients older than 18&#xD;
      years old of age and completed 12 months of dual anti-platelet therapy without having&#xD;
      hemorrhage and ischemic coronary event and with available data of age, history of smoking,&#xD;
      presence of diabetes mellitus, history of percutaneous coronary intervention, paclitaxel&#xD;
      eluting stent, stent diameter, history of myocardial infarction, saphenous vein graft&#xD;
      intervention, ejection fraction or presence of heart failure. Patients that do not approve&#xD;
      informed consent will be excluded.&#xD;
&#xD;
      Aim&#xD;
&#xD;
      This study is amid to investigate the demographic and clinical profile of patients with CAD&#xD;
      and on dual anti-platelet therapy, mean precise -DAPT and DAPT scores of Turkey.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ischemia</measure>
    <time_frame>3 months</time_frame>
    <description>ischemic events of patients on dual antiplatelet therapy</description>
  </primary_outcome>
  <enrollment type="Actual">963</enrollment>
  <condition>Anti-platelet Therapy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Demographical and Clinical Profile of Patients on Dual Ant覺platelet Therapy</intervention_name>
    <description>Demographical and Clinical Profile of Patients on Dual Ant覺platelet Therapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have acute coronary syndrome or percutaneous coronary intervention electively&#xD;
        and with available admission heamoglobin, white blood cell and creatine clearance data and&#xD;
        on dual antiplatelet therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that have acute coronary syndrome or percutaneous coronary intervention&#xD;
             electively and with available admission heamoglobin, white blood cell and creatine&#xD;
             clearance data and on dual antiplatelet therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being under eighteen years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Balikesir University</name>
      <address>
        <city>Balikesir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

